A systematic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after COVID-19
Rheumatology International · 2023
DOI: 10.1007/s00296-023-05283-9 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Rheumatology International, 2023. Verfasst von Koushan Kouranloo und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Liverpool, Ashon St., Liverpool, L69 3GE, UK. k.kouranloo@doctors.net.uk. Hauptthemen laut MEDLINE: Mixed Connective Tissue Disease, COVID-19, Connective Tissue Diseases, Autoimmune Diseases. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
A literature review on new-onset autoimmune connective tissue diseases (ACTDs) following COVID-19 is lacking. We evaluated potential associations between COVID-19 and the development of new-onset ACTDs. The “population” was adults with disease terms for ACTDs, including systemic lupus erythematosus (SLE), Sjogren’s syndrome, systemic sclerosis (SSc), idiopathic inflammatory myositis (IIM), anti-synthetase syndrome, mixed CTD and undifferentiated CTD, and “intervention” as COVID-19 and related terms. Databases were searched for English-language articles published until September 2022. We identified 2236 articles with 28 ultimately included. Of the 28 included patients, 64.3% were female, with a mean age was 51.1 years. The USA reported the most cases (9/28). ACTD diagnoses comprised: 11 (39.3%) IIM (including four dermatomyositis); 7 (25%) SLE; four (14.3%) anti-synthetase syndrome; four (14.3%) SSc; two (7.1%) other ACTD (one lupus/MCTD overlap). Of eight, four (14.3%) patients (including that with lupus/MCTD) had lupus nephritis. The average time from COVID-19 to ACTD diagnosis was 23.7 days. A third of patients were admitted to critical care, one for treatment of haemophagocytic lymphohistiocytosis in SLE (14 sessions of plasmapheresis, rituximab and intravenous corticosteroids) and nine due to COVID-19. 80% of patients went into remission of ACTD following treatment, while three (10%) patients died—one due to macrophage activation syndrome with anti-synthetase syndrome and two from unreported causes. Our results suggest a potential association between COVID-19 and new-onset ACTDs, notably in young females, reflecting more comprehensive CTD epidemiology. The most common diagnosis in our cohort was IIM. The aetiology and mechanisms by which ACTDs emerge following COVID-19 remain unknown and require further research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, University of Liverpool, Ashon St., Liverpool, L69 3GE, UK. k.kouranloo@doctors.net.uk.
- Royal Liverpool University NHS Foundation Trust, Prescot St., Liverpool, L7 8XP, UK. k.kouranloo@doctors.net.uk.
- Department of Rheumatology, Queen Elizabeth Hospital, Stadium Rd., London, SE18 4QH, UK.
- Institute of Life Health Sciences, University of Liverpool, Liverpool, L7 8TX, UK.
- BMA Library, BMA House, Tavistock Square, British Medical Association, London, WC1H 9JP, UK.
- Department of Rheumatology, Southport and Ormskirk NHS Foundation Trust, Southport, PR8 6PN, UK.
ORCID-Profile: Koushan Kouranloo
Zitieren
APA
Kouranloo, K., Dey, M., Elwell, H., & Nune, A. (2023). A systematic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after COVID-19. Rheumatology International. https://doi.org/10.1007/s00296-023-05283-9
Vancouver
Kouranloo K, Dey M, Elwell H, Nune A. A systematic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after COVID-19. Rheumatology International. 2023. doi:10.1007/s00296-023-05283-9
BibTeX
@article{Kouranloo2023,
author = {Kouranloo, Koushan and Dey, Mrinalini and Elwell, Helen and Nune, Arvind},
title = {A systematic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after COVID-19},
journal = {Rheumatology International},
year = {2023},
doi = {10.1007/s00296-023-05283-9}
}
EUVIMED